The CNR1 gene as a pharmacogenetic factor for antipsychotics rather than a susceptibility gene for schizophrenia

[1]  T. Meitinger,et al.  No evidence for an involvement of variants in the cannabinoid receptor gene (CNR1) in obesity in German children and adolescents. , 2007, Molecular genetics and metabolism.

[2]  S. Purcell,et al.  Cannabis receptor haplotype associated with fewer cannabis dependence symptoms in adolescents , 2006, American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics.

[3]  M. Krebs,et al.  (AAT)n repeat in the cannabinoid receptor gene (CNR1): association with cocaine addiction in an African-Caribbean population , 2006, The Pharmacogenomics Journal.

[4]  J. Os,et al.  Prospective cohort study of cannabis use, predisposition for psychosis, and psychotic symptoms in young people , 2004, BMJ : British Medical Journal.

[5]  J. Scharfetter.  Psychopharmacogenetics of schizophrenia and psychosis , 2006 .

[6]  P. Gorwood,et al.  Introduction on psychopharmacogenetics , 2006 .

[7]  J. Ioannidis,et al.  Hardy–Weinberg equilibrium in genetic association studies: an empirical evaluation of reporting, deviations, and power , 2005, European Journal of Human Genetics.

[8]  A. Caspi,et al.  Moderation of the Effect of Adolescent-Onset Cannabis Use on Adult Psychosis by a Functional Polymorphism in the Catechol-O-Methyltransferase Gene: Longitudinal Evidence of a Gene X Environment Interaction , 2005, Biological Psychiatry.

[9]  P. Gorwood,et al.  Negative symptoms of schizophrenia could explain discrepant data on the association between the 5-HT2A receptor gene and response to antipsychotics , 2005, Neuroscience Letters.

[10]  Ralitza Gueorguieva,et al.  Delta-9-tetrahydrocannabinol effects in schizophrenia: Implications for cognition, psychosis, and addiction , 2005, Biological Psychiatry.

[11]  A. Zuardi,et al.  Effects of cannabidiol in animal models predictive of antipsychotic activity , 2005, Psychopharmacology.

[12]  J. Hoenicka,et al.  Depression in Parkinson's disease is related to a genetic polymorphism of the cannabinoid receptor gene (CNR1) , 2005, The Pharmacogenomics Journal.

[13]  G. Uhl,et al.  Human cannabinoid receptor 1: 5′ exons, candidate regulatory regions, polymorphisms, haplotypes and association with polysubstance abuse , 2004, Molecular Psychiatry.

[14]  J. Lieberman,et al.  First episode schizophrenia-related psychosis and substance use disorders: acute response to olanzapine and haloperidol , 2004, Schizophrenia Research.

[15]  R. Murray,et al.  Causal association between cannabis and psychosis: examination of the evidence , 2004, British Journal of Psychiatry.

[16]  B. Bondy,et al.  Alcoholism-related phenotypes and genetic variants of the CB1 receptor , 2003, European Archives of Psychiatry and Clinical Neuroscience.

[17]  P. Casti,et al.  Haloperidol, but not clozapine, produces dramatic catalepsy in Δ9‐THC‐treated rats: possible clinical implications , 2003, British journal of pharmacology.

[18]  M. Krebs,et al.  [Cannabis and schizophrenia: demographic and clinical correlates]. , 2003, L'Encephale.

[19]  P. Gorwood,et al.  Association of 5-HT2A receptor gene polymorphism with major affective disorders: the case of a subgroup of bipolar disorder with low suicide risk , 2002, Biological Psychiatry.

[20]  G. Uhl,et al.  Endocannabinoids and cannabinoid receptor genetics , 2002, Progress in Neurobiology.

[21]  G. Kotzalidis,et al.  Cannabis and schizophrenia: impact on onset, course, psychopathology and outcomes , 2002, European Archives of Psychiatry and Clinical Neuroscience.

[22]  J. Samochowiec,et al.  Association of a CB1 cannabinoid receptor gene (CNR1) polymorphism with severe alcohol dependence. , 2002, Drug and alcohol dependence.

[23]  H Ujike,et al.  CNR1, central cannabinoid receptor gene, associated with susceptibility to hebephrenic schizophrenia , 2002, Molecular Psychiatry.

[24]  N. Griffon,et al.  Schizophrenia and the cannabinoid receptor type 1 (CB1): association study using a single-base polymorphism in coding exon 1. , 2001, American journal of medical genetics.

[25]  Marie-Odile Krebs,et al.  Substance abuse and suicidality in schizophrenia: a common risk factor linked to impulsivity , 2001, Psychiatry Research.

[26]  S. Tsai,et al.  Association study between cannabinoid receptor gene (CNR1) and pathogenesis and psychotic symptoms of mood disorders. , 2001, American journal of medical genetics.

[27]  M. Rietschel,et al.  Pharmacogenetics of clozapine response , 2000, The Lancet.

[28]  D. Collier,et al.  No association between (AAT)n repeats in the cannabinoid receptor gene (CNR1) and heroin abuse in a Chinese population , 2000, Molecular Psychiatry.

[29]  K. Müller-Vahl,et al.  A frequent polymorphism in the coding exon of the human cannabinoid receptor (CNR1) gene. , 1999, Molecular and cellular probes.

[30]  P. Tu,et al.  No evidence for association of serotonin-2A receptor variant (102T/C) with schizophrenia or clozapine response in a Chinese population. , 1999, Neuroreport.

[31]  D. Collier,et al.  Evidence for association between polymorphisms in the promoter and coding regions of the 5-HT2A receptor gene and response to clozapine , 1998, Molecular Psychiatry.

[32]  E. Gershon,et al.  Suggestive evidence for a schizophrenia susceptibility locus on chromosome 6q and a confirmation in an independent series of pedigrees. , 1997, Genomics.

[33]  D. Comings,et al.  Cannabinoid receptor gene (CNR1): association with IV drug use , 1997, Molecular Psychiatry.

[34]  R. Murray,et al.  Morbid risk of schizophrenia for relatives of patients with cannabis-associated psychosis , 1995, Schizophrenia Research.

[35]  J. Nurnberger,et al.  Diagnostic interview for genetic studies. Rationale, unique features, and training. NIMH Genetics Initiative. , 1994, Archives of general psychiatry.

[36]  N. Rector,et al.  Current cannabis use and tardive dyskinesia , 1993, Schizophrenia Research.

[37]  R. Liberman,et al.  At Issue: Defining Treatment Refractoriness in Schizophrenia , 1990 .

[38]  D. Hosmer,et al.  Applied Logistic Regression , 1991 .

[39]  Sven Andréasson,et al.  CANNABIS AND SCHIZOPHRENIA A Longitudinal Study of Swedish Conscripts , 1987, The Lancet.

[40]  G. Simpson,et al.  A RATING SCALE FOR EXTRAPYRAMIDAL SIDE EFFECTS , 1970, Acta psychiatrica Scandinavica. Supplementum.

[41]  P. Armitage.  Tests for Linear Trends in Proportions and Frequencies , 1955 .